Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 14, 2023

Durvalumab With or Without Tremelimumab vs the EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic HNSCC

Annals of Oncology


Additional Info

Annals of Oncology
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
Ann. Oncol 2022 Dec 16;[EPub Ahead of Print], A Psyrri, J Fayette, K Harrington, M Gillison, MJ Ahn, S Takahashi, J Weiss, JP Machiels, S Baxi, A Vasilyev, A Karpenko, M Dvorkin, CY Hsieh, SC Thungappa, PP Segura, I Vynnychenko, R Haddad, S Kasper, PS Mauz, V Baker, P He, B Evans, S Wildsmith, RF Olsson, A Yovine, JF Kurland, N Morsli, TY Seiwert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading